BioFactura develops and commercializes biodefense drugs, client-selected novel drugs, and high-value biosimilars..
BioFactura is committed to identifying and fulfilling unmet national biodefense and global biomedical needs..
BioFactura has developed the StableFast™ Biomanufacturing Platform, a novel system to rapidly generate stable..
BioFactura’s biopharmaceutical industry experience is grounded in bioprocess development,scale-up, and manufacturing..
Frederick, Maryland, November 5, 2024: BioFactura, Inc. recently announced contract option activati...
Frederick, Maryland, October 2, 2023: BioFactura, Inc. today announced a contract option activation...
Frederick, Maryland, September 11, 2023: BioFactura, Inc. announced the publication of the phase 1...
Jeffrey N. Hausfeld, Rodeina Challand, Kristi McLendon, Nathaniel Macapagal, Pam Bruce-Staskal, Chri...
Eric M. Mucker, Suzanne E. Wollen-Roberts, Adrienne Kimmel, Josh Shamblin, Darryl Sampey and Jay W....
Darryl Sampey, Pascal Courville, David Acree, Jeffrey Hausfeld and William E. Bentley. Biotechnolog...
Simran J. Kaur, Darryl Sampey, Lester W. Schultheis, Leonard P. Freedman and William E. Bentley. Bi...
Megan M Illick, Luis M Branco, Joseph N Fair, Kerry A Illick, Alex Matschiner, Randal J Schoepp, Rob...
Luis M Branco, Alex Matschiner, Joseph N Fair, Augustine Goba, Darryl B Sampey, Philip J Ferro, Kath...